Hikma intros diazepam injection

Hikma is introducing diazepam injection in a dosage strength of 5mg/mL in 2mL.

The product is indicated for the management of anxiety, convulsive seizures and alcohol withdrawals.

[Read more: Hikma intros Kloxxado]

Hikma noted that Diazepam has been in short supply until recently.

“We are excited to announce the launch of Diazepam injection, our second product in prefilled syringe form which may help treat patients faster, more easily and with reduced risk, particularly in time-sensitive situations,” said Riad Mishlawi, president of Hikma Injectables. “We are continuously expanding our portfolio of essential medicines and introducing new dosage forms that enhance patient care. This launch leverages the investments we have made to expand our Injectables manufacturing capacity and capabilities and we look forward to bringing more medicines in this form to patients and healthcare professionals in the U.S.”

[Read more: Hikma to acquire Custopharm]

Diazepam injection has a market value of approximately $31 million in the 12 months ending November 2021, according to IQVIA.